Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, has announced that it has received Notices of Allowance from the US Patent and Trademark Office for two key patents for lead immuno-oncology candidate APG101.
The so-called method of use patent covers the use of CD95 ligand inhibitors, such as APG101, for the treatment of glioblastoma. This patent is valid at least until 2029. The so-called composition of matter patent protects APG101 as a product as well as its manufacturing process at least until 2033.
“Apogenix already has a broad patent portfolio covering APG101. These two patents greatly expand the protection of APG101 and its use in the treatment of glioblastoma,” said Thomas Hoeger, PhD, CEO of Apogenix. “The prospective granting of these two patents in the most important pharmaceutical market further validates our innovative drug development approach and the therapeutic potential of CD95 ligand inhibitors for the treatment of malignant brain tumours, among other indications.”
The efficacy, safety, and tolerability of APG101 were demonstrated in a controlled Phase II proof-of-concept trial in patients with recurrent glioblastoma. Treatment with APG101 in combination with radiotherapy has shown clinical superiority in all study endpoints compared to treatment with radiotherapy alone, resulting in an overall survival benefit in glioblastoma patients treated with APG101. Interim data of a Phase I trial with APG101 for the treatment of myelodysplastic syndromes further indicate the efficacy of APG101 in this haematological disease.